Roth Capital Downgrades Knowles to Neutral, Lowers Price Target to $17

Roth Capital analyst Suji Desilva downgrades Knowles (NYSE:KN) from Buy to Neutral and lowers the price target from $30 to $17.

byBenzinga Newsdesk

August 3, 2022

1 minute read

Roth Capital analyst Suji Desilva downgrades Knowles (NYSE:KN) from Buy to Neutral and lowers the price target from $30 to $17.

This Rare Disease Focused Stock Pipeline Is Underappreciated, Analyst Initiating Coverage Says

By Vandana Singh

Today, 6:00 AM

Cantor Fitzgerald has initiated coverage on KemPharm Inc (NASDAQ:KMPH) with an Overweight rating and a price target of $20. Per the analyst,…

KMPH

U.S. FDA Approves AbbVie’s RINVOQ® (upadacitinib) for Ankylosing Spondylitis (AS)

By Ragothaman Srinivasan

Today, 6:00 AM

The U.S. Food and Drug Administration (FDA) has approved AbbVie’s (NYSE: ABBV) RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of adults with active ankylosing spondylitis (AS) .

ABBV

Global
News

‘Tesla Upgrading Two China Factory Lines To Boost Output’ – Tweet By CN Wire

By Benzinga Newsdesk

Today, 6:00 AM

https://twitter.com/Sino_Market/status/1539915979211169793

TSLA

Israel-Based Clearmind Medicine Shows Efficacy Of Psychedelic Derived Obesity Treatment In Pre-Clinical Trial

By Benzinga Newsdesk

Today, 6:00 AM

In a series of pre-clinical trials, Clearmind's drug candidate MEAI significantly reduced body weight, improved fatty liver disease, and normalized insulin sensitivity Tel Aviv, Israel / Vancouver, Canada, Jan.

CMND

Roth Capital Downgrades Knowles to Neutral, Lowers Price Target to $17

Related Posts

This Rare Disease Focused Stock Pipeline Is Underappreciated, Analyst Initiating Coverage Says

U.S. FDA Approves AbbVie’s RINVOQ® (upadacitinib) for Ankylosing Spondylitis (AS)

‘Tesla Upgrading Two China Factory Lines To Boost Output’ – Tweet By CN Wire

Israel-Based Clearmind Medicine Shows Efficacy Of Psychedelic Derived Obesity Treatment In Pre-Clinical Trial